Cargando…
Total flavonoids from Rhizoma Drynariae (Gusuibu) for treating osteoporotic fractures: implication in clinical practice
This systematic review was performed to determine the clinical efficacy and safety of total flavonoids from Rhizoma Drynariae (TFRD) for osteoporotic fractures and to provide clear evidence for clinical practice. Eight databases were searched to identify relevant randomized controlled trials (RCTs)...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491704/ https://www.ncbi.nlm.nih.gov/pubmed/28694688 http://dx.doi.org/10.2147/DDDT.S139804 |
_version_ | 1783247184270983168 |
---|---|
author | Zhang, Yili Jiang, Junjie Shen, Hao Chai, Yan Wei, Xu Xie, Yanming |
author_facet | Zhang, Yili Jiang, Junjie Shen, Hao Chai, Yan Wei, Xu Xie, Yanming |
author_sort | Zhang, Yili |
collection | PubMed |
description | This systematic review was performed to determine the clinical efficacy and safety of total flavonoids from Rhizoma Drynariae (TFRD) for osteoporotic fractures and to provide clear evidence for clinical practice. Eight databases were searched to identify relevant randomized controlled trials (RCTs) until December 2016. Six RCTs involving 846 patients were included. The primary outcomes included fracture recurrence and death. Meta-analysis showed that both the combination therapy and TFRD alone were better than conventional treatments in improving bone mineral density (BMD) value (weighted mean difference [WMD] =3.68, 95% confidence interval [CI]: 0.01 to 0.04, P=0.0002), (WMD =0.14; 95% CI: 0.11 to 0.16; P<0.00001), respectively, and enhancing therapeutic effect (OR =0.25; 95% CI: 0.12 to 0.51; P=0.0002). Thirty-three patients experienced adverse drug reactions (ADRs), none of the ADRs were severe and all were resolved after symptomatic treatments. Gastrointestinal symptoms were the most common ADRs in the usage of TFRD. Overall, the effect of TFRD on osteoporotic fractures was supported by improving BMD and therapeutic effect. Due to the methodological drawbacks of the included studies, the conclusions should be treated with caution for future research. Registration number: CRD42017052797. |
format | Online Article Text |
id | pubmed-5491704 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-54917042017-07-10 Total flavonoids from Rhizoma Drynariae (Gusuibu) for treating osteoporotic fractures: implication in clinical practice Zhang, Yili Jiang, Junjie Shen, Hao Chai, Yan Wei, Xu Xie, Yanming Drug Des Devel Ther Review This systematic review was performed to determine the clinical efficacy and safety of total flavonoids from Rhizoma Drynariae (TFRD) for osteoporotic fractures and to provide clear evidence for clinical practice. Eight databases were searched to identify relevant randomized controlled trials (RCTs) until December 2016. Six RCTs involving 846 patients were included. The primary outcomes included fracture recurrence and death. Meta-analysis showed that both the combination therapy and TFRD alone were better than conventional treatments in improving bone mineral density (BMD) value (weighted mean difference [WMD] =3.68, 95% confidence interval [CI]: 0.01 to 0.04, P=0.0002), (WMD =0.14; 95% CI: 0.11 to 0.16; P<0.00001), respectively, and enhancing therapeutic effect (OR =0.25; 95% CI: 0.12 to 0.51; P=0.0002). Thirty-three patients experienced adverse drug reactions (ADRs), none of the ADRs were severe and all were resolved after symptomatic treatments. Gastrointestinal symptoms were the most common ADRs in the usage of TFRD. Overall, the effect of TFRD on osteoporotic fractures was supported by improving BMD and therapeutic effect. Due to the methodological drawbacks of the included studies, the conclusions should be treated with caution for future research. Registration number: CRD42017052797. Dove Medical Press 2017-06-23 /pmc/articles/PMC5491704/ /pubmed/28694688 http://dx.doi.org/10.2147/DDDT.S139804 Text en © 2017 Zhang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Zhang, Yili Jiang, Junjie Shen, Hao Chai, Yan Wei, Xu Xie, Yanming Total flavonoids from Rhizoma Drynariae (Gusuibu) for treating osteoporotic fractures: implication in clinical practice |
title | Total flavonoids from Rhizoma Drynariae (Gusuibu) for treating osteoporotic fractures: implication in clinical practice |
title_full | Total flavonoids from Rhizoma Drynariae (Gusuibu) for treating osteoporotic fractures: implication in clinical practice |
title_fullStr | Total flavonoids from Rhizoma Drynariae (Gusuibu) for treating osteoporotic fractures: implication in clinical practice |
title_full_unstemmed | Total flavonoids from Rhizoma Drynariae (Gusuibu) for treating osteoporotic fractures: implication in clinical practice |
title_short | Total flavonoids from Rhizoma Drynariae (Gusuibu) for treating osteoporotic fractures: implication in clinical practice |
title_sort | total flavonoids from rhizoma drynariae (gusuibu) for treating osteoporotic fractures: implication in clinical practice |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491704/ https://www.ncbi.nlm.nih.gov/pubmed/28694688 http://dx.doi.org/10.2147/DDDT.S139804 |
work_keys_str_mv | AT zhangyili totalflavonoidsfromrhizomadrynariaegusuibufortreatingosteoporoticfracturesimplicationinclinicalpractice AT jiangjunjie totalflavonoidsfromrhizomadrynariaegusuibufortreatingosteoporoticfracturesimplicationinclinicalpractice AT shenhao totalflavonoidsfromrhizomadrynariaegusuibufortreatingosteoporoticfracturesimplicationinclinicalpractice AT chaiyan totalflavonoidsfromrhizomadrynariaegusuibufortreatingosteoporoticfracturesimplicationinclinicalpractice AT weixu totalflavonoidsfromrhizomadrynariaegusuibufortreatingosteoporoticfracturesimplicationinclinicalpractice AT xieyanming totalflavonoidsfromrhizomadrynariaegusuibufortreatingosteoporoticfracturesimplicationinclinicalpractice |